TG Therapeutics (TGTX) Competitors $34.65 -0.22 (-0.63%) As of 10:48 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock TGTX vs. GMAB, SMMT, ASND, RDY, VTRS, ROIV, BBIO, MRNA, QGEN, and ELANShould you be buying TG Therapeutics stock or one of its competitors? The main competitors of TG Therapeutics include Genmab A/S (GMAB), Summit Therapeutics (SMMT), Ascendis Pharma A/S (ASND), Dr. Reddy's Laboratories (RDY), Viatris (VTRS), Roivant Sciences (ROIV), BridgeBio Pharma (BBIO), Moderna (MRNA), QIAGEN (QGEN), and Elanco Animal Health (ELAN). These companies are all part of the "pharmaceutical products" industry. TG Therapeutics vs. Its Competitors Genmab A/S Summit Therapeutics Ascendis Pharma A/S Dr. Reddy's Laboratories Viatris Roivant Sciences BridgeBio Pharma Moderna QIAGEN Elanco Animal Health TG Therapeutics (NASDAQ:TGTX) and Genmab A/S (NASDAQ:GMAB) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, earnings, media sentiment, profitability, analyst recommendations, risk and valuation. Which has more volatility and risk, TGTX or GMAB? TG Therapeutics has a beta of 1.97, indicating that its share price is 97% more volatile than the S&P 500. Comparatively, Genmab A/S has a beta of 0.98, indicating that its share price is 2% less volatile than the S&P 500. Which has stronger earnings & valuation, TGTX or GMAB? Genmab A/S has higher revenue and earnings than TG Therapeutics. Genmab A/S is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTG Therapeutics$329M16.71$23.38M$0.3793.65Genmab A/S$3.12B6.74$1.14B$1.9916.48 Does the media prefer TGTX or GMAB? In the previous week, Genmab A/S had 27 more articles in the media than TG Therapeutics. MarketBeat recorded 28 mentions for Genmab A/S and 1 mentions for TG Therapeutics. TG Therapeutics' average media sentiment score of 0.78 beat Genmab A/S's score of 0.66 indicating that TG Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TG Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Genmab A/S 8 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend TGTX or GMAB? TG Therapeutics currently has a consensus target price of $49.00, indicating a potential upside of 41.41%. Genmab A/S has a consensus target price of $40.80, indicating a potential upside of 24.41%. Given TG Therapeutics' higher possible upside, equities analysts plainly believe TG Therapeutics is more favorable than Genmab A/S.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TG Therapeutics 0 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.67Genmab A/S 1 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 2.82 Do institutionals and insiders believe in TGTX or GMAB? 58.6% of TG Therapeutics shares are owned by institutional investors. Comparatively, 7.1% of Genmab A/S shares are owned by institutional investors. 10.6% of TG Therapeutics shares are owned by company insiders. Comparatively, 1.5% of Genmab A/S shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Is TGTX or GMAB more profitable? Genmab A/S has a net margin of 37.53% compared to TG Therapeutics' net margin of 13.31%. TG Therapeutics' return on equity of 26.05% beat Genmab A/S's return on equity.Company Net Margins Return on Equity Return on Assets TG Therapeutics13.31% 26.05% 9.58% Genmab A/S 37.53%21.03%16.98% SummaryGenmab A/S beats TG Therapeutics on 9 of the 17 factors compared between the two stocks. Get TG Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TGTX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TGTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TGTX vs. The Competition Export to ExcelMetricTG TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.48B$3.42B$6.10B$10.49BDividend YieldN/A2.29%5.73%4.78%P/E Ratio93.3923.0484.6327.17Price / Sales16.71484.44608.51132.45Price / Cash292.1746.9737.8662.13Price / Book24.2310.5112.356.62Net Income$23.38M-$52.47M$3.33B$276.88M7 Day Performance2.64%3.06%2.11%1.49%1 Month Performance8.15%15.52%9.40%4.79%1 Year Performance44.74%13.77%73.46%36.32% TG Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TGTXTG Therapeutics4.4125 of 5 stars$34.65-0.6%$49.00+41.4%+42.3%$5.48B$329M93.39290GMABGenmab A/S3.7565 of 5 stars$32.68+2.7%$40.80+24.8%+44.9%$20.42B$3.12B16.422,682Trending NewsAnalyst ForecastShort Interest ↑Analyst RevisionSMMTSummit Therapeutics3.0162 of 5 stars$22.93+7.4%$31.29+36.4%-6.4%$15.86B$700K-22.70110Upcoming EarningsASNDAscendis Pharma A/S2.8766 of 5 stars$208.43-0.5%$248.29+19.1%+58.9%$12.93B$393.54M-40.391,017News CoverageAnalyst ForecastAnalyst RevisionGap UpRDYDr. Reddy's Laboratories3.1513 of 5 stars$14.36+0.1%$16.95+18.1%-10.1%$11.97B$3.81B21.7527,811Positive NewsVTRSViatris3.1067 of 5 stars$9.86+1.2%$10.40+5.5%-14.6%$11.36B$14.74B-3.4032,000News CoverageAnalyst ForecastROIVRoivant Sciences3.0735 of 5 stars$16.21+1.1%$19.94+23.0%+42.9%$10.95B$29.05M-23.16860Insider TradeBBIOBridgeBio Pharma4.4949 of 5 stars$55.96+0.8%$63.94+14.3%+108.9%$10.61B$221.90M-13.68400Positive NewsAnalyst RevisionMRNAModerna4.2459 of 5 stars$26.74-0.3%$41.81+56.4%-52.8%$10.48B$3.24B-3.555,800Analyst RevisionGap DownQGENQIAGEN4.1228 of 5 stars$47.30+1.0%$49.40+4.4%+14.5%$10.41B$1.98B27.955,765ELANElanco Animal Health2.5478 of 5 stars$20.04+1.4%$19.14-4.5%+54.6%$9.82B$4.44B23.309,000Analyst Revision Related Companies and Tools Related Companies Genmab A/S Alternatives Summit Therapeutics Alternatives Ascendis Pharma A/S Alternatives Dr. Reddy's Laboratories Alternatives Viatris Alternatives Roivant Sciences Alternatives BridgeBio Pharma Alternatives Moderna Alternatives QIAGEN Alternatives Elanco Animal Health Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TGTX) was last updated on 10/17/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredThe Army Just Got a New Drone SupplierA cutting-edge drone developer just secured a U.S. Army deal to supply its Flex FPV Modular Drones and build a...The Tomorrow Investor | SponsoredElon’s Out 🚫. Trump’s DOGE Payouts Keep Flowing (Up to $32K a Year)DOGE payouts are already moving. Every 90 days, billions flow out — whether you’ve claimed your share or not. ...Angel Publishing | SponsoredMove $1,000 into this stock before Nov 6The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TG Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TG Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
